Search by Drug Name or NDC
NDC 00074-4339-02 Humira Details
Humira
Humira is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is .
MedlinePlus Drug Summary
Adalimumab injection products are used alone or with other medications to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system attacks healthy parts of the body and causes pain, swelling, and damage) including the following: rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in adults, juvenile idiopathic arthritis (JIA; a condition that affects children in which the body attacks its own joints, causing pain, swelling, loss of function, and delays in growth and development) in children 2 years of age and older, Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) that has not improved when treated with other medications in adults and children 6 years of age and older, ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) when other medications and treatments did not help or could not be tolerated in adults and children 5 years of age and older, ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas causing pain and joint damage) in adults, psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin) in adults, hidradenitis suppurativa (a skin disease that causes pimple-like bumps in the armpits, groin, and anal area) in adults and children 12 years of age and older, uveitis (swelling and inflammation of different areas of the eye) in adults and children 2 years of age and older, chronic plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults. Adalimumab injection products are in a class of medications called tumor necrosis factor (TNF) inhibitors. They work by blocking the action of TNF, a substance in the body that causes inflammation.
Related Packages: 00074-4339-02Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Adalimumab Injection
Product Information
NDC | 00074-4339 |
---|---|
Product ID | 0074-4339_17d70a36-5bb6-43f0-add4-490aafac7ce3 |
Associated GPIs | 6627001500F420 |
GCN Sequence Number | 061205 |
GCN Sequence Number Description | adalimumab PEN IJ KIT 40MG/0.8ML SUBCUT |
HIC3 | S2J |
HIC3 Description | ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR |
GCN | 97005 |
HICL Sequence Number | 024800 |
HICL Sequence Number Description | ADALIMUMAB |
Brand/Generic | Brand |
Proprietary Name | Humira |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Adalimumab |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | KIT |
Route | n/a |
Active Ingredient Strength | n/a |
Active Ingredient Units | n/a |
Substance Name | n/a |
Labeler Name | AbbVie Inc. |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA125057 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00074-4339-02 (00074433902)
NDC Package Code | 0074-4339-02 |
---|---|
Billing NDC | 00074433902 |
Package | 2 KIT in 1 CARTON (0074-4339-02) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .8 mL in 1 SYRINGE * 1 mL in 1 PACKET |
Marketing Start Date | 2006-06-23 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 3369.69 |
Pricing Unit | EA |
Effective Date | 2024-02-21 |
NDC Description | HUMIRA PEN 40 MG/0.8 ML |
Pharmacy Type Indicator | C/I |
OTC | N |
Explanation Code | 1, 5 |
Classification for Rate Setting | B |
As of Date | 2024-02-21 |